[EATG Global HIV News daily digest] Digest #17-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  U.S.
Food and Drug Administration approves labeling update for PREZISTA(R)
to include 96-week data in HIV-1 infected adult patients
  Treatment Thursday 28 January 2010
					
  
Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA
with ritonavir (r) vs. lopinavir/r in combination with other ARVs for
the treatment of HIV-1 in treatment-naive and treatment-experienced
adult patients, respectively. 
  SOURCE:
Tibotec Therapeutics




  EC will keep pressure on pharma sector, say lawyers 
  EU Policy Thursday 28 January 2010
					
  
Drugmakers need to review their patent settlement agreements as a form
of due diligence as the European Commission maintains its scrutiny of
the pharmaceuticals sector, according to a leading law firm.
  SOURCE:
PharmaTimes




  New Parliament group monitors EU trade pacts’ impact on poor’s medicines access 
  EU Policy Thursday 28 January 2010
					
  
Trade agreements must not contain clauses on intellectual property
rights that could imperil the poor’s access to affordable medicines, a
veteran member of the European Parliament (MEP) has said.
  SOURCE:
Intellectual Property Watch




  Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA
  Pharma Industry Thursday 28 January 2010
					
  
Viread is currently protected by four patents, which are listed in the
FDA’s Approved Drug Products List, and all four patents would need to
be invalidated or expired before a generic version of Viread could be
marketed. 
  SOURCE:
The Medical News




  Particle Sciences to share responsibilities in developing anti-HIV microbicides
  Prevention Thursday 28 January 2010
					
  
The program will include human studies to determine microbicide safety
and will investigate biomarkers associated with health or damage at
mucosal surfaces. It will also encompass formulation development and
manufacturing process scale-up of the drug product. 
  SOURCE:
The Medical News




  Achillion announces nomination of ACH-2684 as lead clinical candidate in resistance-focused HCV program
  Hepatitis Thursday 28 January 2010
					
  
Compound demonstrates excellent potency against HCV and retains activity against resistant variants.
  SOURCE:
Achillion Pharmaceuticals, Inc.




  Long-lasting HIV nucleoside analogue in development
  Treatment Thursday 28 January 2010
					
  
"This new compound, EFdA, is 60,000 times more potent than any other drug that is currently being used to treat HIV."
  SOURCE:
AIDSmeds.com




  Genetic marker may predict heart disease risk in people with HIV 
  Treatment Thursday 28 January 2010
					
  
A genetic marker associated with atherosclerosis and oxidative stress
in mice and humans is strongly associated with the incidence of
cardiovascular disease, metabolic syndrome and poorer immune recovery
in people with HIV.
  SOURCE:
Aidsmap




  New criteria proposed for late HIV diagnosis 
  Treatment Thursday 28 January 2010
					
  
New definitions of both late HIV diagnosis and diagnosis with advanced HIV disease have been proposed by UK investigators. 
  SOURCE:
Aidsmap




  Kidney dysfunction more frequent, increases risk of death of patients with HIV and hepatitis C co-infection 
  Hepatitis Thursday 28 January 2010
					
  
Hepatitis C co-infection is associated with an increased risk of kidney
disease and death for HIV-positive individuals, US investigators report
in the February 1st edition of the Journal of Acquired Immune
Deficiency Syndromes. 
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100128/906a31c2/attachment-0001.html>